Table 1 Baseline patient characteristics.
From: Targeting continuity of care and polypharmacy to reduce drug–drug interaction
Variables | Low COC group | High COC group | P valuea | All patients |
|---|---|---|---|---|
N | 1,159,069 | 1,159,697 | 2,318,766 | |
COCI [mean(SD)] | 0.15(0.06) | 0.46(0.21) | < 0.001 | 0.30(0.22) |
Age in 2011 [mean(SD)] | 74.71(6.94) | 74.72(6.96) | 0.382 | 74.71(6.95) |
Age group [n (%)] | < 0.001 | |||
65–74 | 629,334(54.30) | 634,364(54.70) | 1,263,698(54.50) | |
75–84 | 412,402(35.58) | 406,122(35.02) | 818,524(35.30) | |
85+ | 117,333(10.12) | 119,211(10.28) | 236,544(10.20) | |
Gender [n (%)] | < 0.001 | |||
Male | 532,303(49.26) | 548,359(50.74) | 1,080,662(46.61) | |
Female | 626,766(50.62) | 611,338(49.38) | 1,238,104(53.39) | |
Physician visits [mean(SD)] | 35.05(23.44) | 25.25(17.91) | < 0.001 | 30.15(21.42) |
Physician visits frequency [n(%)] | < 0.001 | |||
Low | 306,827(26.47) | 487,507(42.04) | 794,334(34.26) | |
Intermediate | 347,785(30.01) | 422,063(36.39) | 769,848(33.20) | |
High | 504,457(43.52) | 250,127(21.57) | 754,584(32.54) | |
No. of prescribed medications [mean(SD)] | 11.29(6.41) | 8.17(4.81) | < 0.001 | 9.73(5.88) |
Polypharmacy status [n(%)] | < 0.001 | |||
No | 66,193(5.71) | 141,473(12.20) | 207,666(8.96) | |
Yes | 1,092,876(94.29) | 1,018,224(87.80) | 2,111,100(91.04) | |
Drug–drug interaction events [n(%)] | < 0.001 | |||
No | 1,104,885(95.32) | 1,135,212(97.88) | 2,240,097(96.60) | |
Yes | 54,184(4.67) | 24,485(2.11) | 78,669(3.39) |
